Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Non-Current Deffered Revenue: 2015-2021

Historic Non-Current Deffered Revenue for Syndax Pharmaceuticals (SNDX) over the last 5 years, with Jun 2021 value amounting to $10.9 million.

  • Syndax Pharmaceuticals' Non-Current Deffered Revenue fell 12.25% to $10.9 million in Q2 2021 from the same period last year, while for Jun 2021 it was $10.9 million, marking a year-over-year decrease of 12.25%. This contributed to the annual value of $11.6 million for FY2020, which is 11.54% down from last year.
  • According to the latest figures from Q2 2021, Syndax Pharmaceuticals' Non-Current Deffered Revenue is $10.9 million, which was down 3.36% from $11.2 million recorded in Q1 2021.
  • Syndax Pharmaceuticals' 5-year Non-Current Deffered Revenue high stood at $16.8 million for Q4 2017, and its period low was $10.9 million during Q2 2021.
  • In the last 3 years, Syndax Pharmaceuticals' Non-Current Deffered Revenue had a median value of $12.6 million in 2020 and averaged $12.6 million.
  • As far as peak fluctuations go, Syndax Pharmaceuticals' Non-Current Deffered Revenue climbed by 17.86% in 2017, and later fell by 12.58% in 2018.
  • Syndax Pharmaceuticals' Non-Current Deffered Revenue (Quarterly) stood at $16.8 million in 2017, then fell by 12.58% to $14.7 million in 2018, then fell by 10.35% to $13.1 million in 2019, then fell by 11.54% to $11.6 million in 2020, then dropped by 12.25% to $10.9 million in 2021.
  • Its last three reported values are $10.9 million in Q2 2021, $11.2 million for Q1 2021, and $11.6 million during Q4 2020.